BeautyHealth's SkinStylus Receives New FDA Clearance For Facial Acne Scarring
Portfolio Pulse from Happy Mohamed
The Beauty Health Company's (NASDAQ:SKIN) SkinStylus microneedling device has received FDA clearance for use on facial acne scarring, making it the only such device cleared for both face and abdomen. This comes five months after BeautyHealth's acquisition of the brand. The microneedling market is expected to reach $1 billion by 2030.
August 04, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BeautyHealth's SkinStylus has received FDA clearance for use on facial acne scarring. This could potentially boost the company's market position.
The FDA clearance of SkinStylus for use on facial acne scarring expands the product's potential market, which could lead to increased sales and revenue for BeautyHealth. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100